# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational...
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investiga...
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combi...
FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents ...